Search

The article presents a case study of a 70-year-old patient, from consanguineous nonaffected parents, was followed up for a congenital transgrediens PPK with classical clinical features of MDM. Topics discussed include diagnosis of metastatic melanoma of the left inguinal lymph nodes; cutaneous malignancies found on palmoplantar keratoderma sites; and diagnosis of amelanotic melanoma arising in an area of SLURP-1 mutated Mal de Meleda.

Background: Lyell's syndrome (SL) or toxic epidermal necrolysis is a rare mucocutaneous eruption, which is characterised by an acute necrosis of the totality of the epidermis +/- the mucosal epithelium. This is a serious affection considering the severity of systemic manifestations, the unpredictable evolution, and the absence of specific therapy., Aim: To assess epidemiological and clinical features of this condition in our departments., Methods: This was a retrospective study concerning the cases of Lyell's syndrome carried in the dermatology and the intensive care department of Farhat Hached hospital over a 26 year period., Results: We listed 12 women and 4 with a mean age of 48.9 years. Epidermal detachment varied between 26 and 80% of the body surface and mucus were involved in 87.5% of cases. Systemic manifestations were noted in 11 patients. A drug etiology was found in 87,5% of cases, half of which was due to antibiotics., Conclusion: Our results are similar to those in the literature. Our study illustrates the severity of this toxiderma with a high mortality rate (43.75% of cases), conformable with what was predicted by the severity-of-illness score "SCORTEN". Infectious complications were the principal cause of death.

Systemic treatment of onychomycosis is based these last years on the new drug utilization aiming to decrease the length of the treatment and secondary effects particularly with fluconazole. The aim of our study is to determine the efficiency and the tolerance of the fluconazole (Funzol) managed to the dose of 150 mg per week in the treatment of onychomycosis. It is a multicentric and prospective study done to different department of dermatology in Tunisia. Are included adult patients with clinical and mycologic documented onychomycosis. They are treated during 12 to 24 weeks for the fingernail and 24 to 36 weeks for the toenail. The assessment of the efficiency and the tolerance of the drug was clinic and biologic. During this survey, 86 patients are included, 55 female and 31 male with mean age of 43.5 years. Onychomycosis seat to hands in 30 cases (34.8%) with a predominance of Candida species (73%), to toes in 68 cases (79%) witch due in 85% of cases to dermatophytic agent (85%). At 6 months, clinical cure rate is observed in 51% of cases. After 9 months, at the end of therapy, 84% of patients were judged clinical successes and culture was negative in 82% of cases. Some minimal secondary effects are signalled in 11% of cases to 6 weeks and 10% to 12 weeks not justifying the stop of the treatment. So this study confirms the efficiency and the good tolerance of fluconazole in the treatment of onychomycosis.